Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis

Garattini, Livio; Cornago, Dante; Compadri, Paola De

doi:10.1016/j.healthpol.2006.11.004

Cited by 59 publications

(34 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, it is not easy to definitively state what constitutes a HCM and the literature is scarce in this regard. A definition is required in-order to place boundaries around this systematic review and to provide context for the synthesis of issues as the primary output of this paper [5].…”

Section: Background and Rationalementioning

confidence: 99%

Identifying stakeholder opinion regarding access to “high-cost medicines”: A systematic review of the literature

et al. 2014

View full text Add to dashboard Cite

AbstractObjective: To identify the viewpoints and perceptions of different stakeholders regarding high cost medicines (HCMs). Methods: A systematic review of the literature was performed to identify original research articles. Using predefined categories, data related to the viewpoints of different stakeholders was systematically extracted and analyzed. Results: Thirty seven original research articles matched the criteria. The main stakeholders identified include physicians, patients, public and health funding authorities. The influence of media and other economic and ethical issues were also identified in the literature. A large number of stakeholders were concerned about lack of access to HCMs. Physicians have difficulty balancing the the rational use of expensive drugs while at the same time acting as “patients’ advocate”. Patients would like to know about all treatment options, even if they may not be able to afford them. The process and criteria for reimbursement should be transparent and access has to be equitable across patient groups. Conclusion: Access to HCMs could be improved through transparency and involvement of all stakeholders, especially patients and the public. Moral issues and the “rule of rescue” could influence decision-making process significantly. At system level, objectivity is important to ensure that the system is equitable and transparent.

show abstract

Section: Background and Rationalementioning

confidence: 99%

Identifying stakeholder opinion regarding access to “high-cost medicines”: A systematic review of the literature

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Although the vast majority of pharmaceutical companies are multinationals nowadays and so many national differences have been smoothed, the presence of an important national pharmaceutical industry has historically affected the national policies of the major European countries [1]. For instance, the positive contribution to domestic economies (in terms of employment and trade export) favored a positive attitude towards the pharmaceutical industry in northern countries like Germany and the UK.…”

Section: Introductionmentioning

confidence: 99%

Competition in pharmaceuticals: more product- than price-oriented?

Garattini

Padula

2017

Eur J Health Econ

Self Cite

View full text Add to dashboard Cite

“…2 After centralised drug registration for market approval by the European Medicines Agency, the regulatory procedure of an ethical drug proceeds at national level for pricing and reimbursement. The management of this process can vary a lot by country.…”

Section: Eu Regulatory Proceduresmentioning

confidence: 99%